WHO ICTRP trial
Assessing safety and efficacy of pembrolizumab in patients with head and neck…
EUCTR2017-003636-36-GB · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2017-003636-36-GB |
|---|---|
| Public title | Assessing safety and efficacy of pembrolizumab in patients with head and neck cancer. |
| Scientific title | A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck - POPPY |
| Primary sponsor | University College London |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United Kingdom |
| Conditions | Recurrent/metastatic head and neck squamous cell cancer MedDRA version: 21.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and… |
| Interventions | Trade Name: Pembrolizumab Product Name: Pembrolizumab Product Code: MK-3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: pembrolizumab CAS Number: 1374853-91-4 Current Sponsor code: MK-3475 Other descriptive name… |
| Registration date | Dec 9, 2018 |
| Target size | 65 |
| Secondary IDs | UCL/17/0396 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: